Brief introduction of 70-23-5

This literature about this compound(70-23-5)Reference of Ethyl 3-bromo-2-oxopropanoatehas given us a lot of inspiration, and I hope that the research on this compound(Ethyl 3-bromo-2-oxopropanoate) can be further advanced. Maybe we can get more compounds in a similar way.

The chemical properties of alicyclic heterocycles are similar to those of the corresponding chain compounds. Compound: Ethyl 3-bromo-2-oxopropanoate, is researched, Molecular C5H7BrO3, CAS is 70-23-5, about Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth, the main research direction is imidazole preparation malignant gene expression suppression antitumor; Cancer therapeutics; MLL-rearranged leukemia; Protein-protein interaction; Small-molecule inhibitor; Super elongation complexes.Reference of Ethyl 3-bromo-2-oxopropanoate.

Chromosome translocations involving mixed lineage leukemia (MLL) gene cause acute leukemia with a poor prognosis. MLL is frequently fused with transcription cofactors AF4 (~35%), AF9 (25%) or its paralog ENL (10%). The AHD domain of AF9/ENL binds to AF4, its paralog AFF4, or histone-H3 lysine-79 (H3K79) methyltransferase DOT1L. Formation of AF9/ENL/AF4/AFF4-containing super elongation complexes (SEC) and the catalytic activity of DOT1L are essential for MLL-rearranged leukemia. Protein-protein interactions (PPI) between AF9/ENL and DOT1L/AF4/AFF4 are therefore a potential drug target. Compound I was identified to be a novel small-mol. inhibitor of the AF9/ENL-DOT1L/ AF4/AFF4 interaction with IC50s of 0.9-3.5μM. Pharmacol. inhibition of the PPIs significantly reduced SEC and DOT1L-mediated H3K79 methylation in the leukemia cells. Gene profiling shows compound I significantly suppressed the gene signatures related to onco-MLL, DOT1L, HoxA9 and Myc. It selectively inhibited proliferation of onco-MLL- or Myc-driven cancer cells and induced cell differentiation and apoptosis. Compound I exhibited strong antitumor activity in a mouse model of MLL-rearranged leukemia. The AF9/ENL-DOT1L/AF4/AFF4 interactions are validated to be an anticancer target and compound I is a useful in vivo probe for biol. studies as well as a pharmacol. lead for further drug development.

This literature about this compound(70-23-5)Reference of Ethyl 3-bromo-2-oxopropanoatehas given us a lot of inspiration, and I hope that the research on this compound(Ethyl 3-bromo-2-oxopropanoate) can be further advanced. Maybe we can get more compounds in a similar way.

Reference:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem